PubRank

Yasuo Saijo

Author PubWeight™ 76.05‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010 27.12
2 Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006 6.55
3 First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009 4.05
4 Severe acute interstitial pneumonia and gefitinib. Lancet 2003 3.94
5 Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. J Clin Invest 2005 2.20
6 Methylation of the KEAP1 gene promoter region in human colorectal cancer. BMC Cancer 2012 2.01
7 Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008 1.88
8 Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig 2013 1.70
9 Paracrine factors of multipotent stromal cells ameliorate lung injury in an elastase-induced emphysema model. Mol Ther 2010 1.39
10 Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells. Stem Cells 2007 1.35
11 Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization. Mol Med 2011 1.31
12 Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res 2002 1.22
13 OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice. J Clin Invest 2007 1.21
14 High level of vascular endothelial growth factor in hemorrhagic pleural effusion of cancer. Oncology 2002 1.04
15 Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations. J Thorac Oncol 2011 1.03
16 Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts. Cancer Res 2004 1.01
17 Mesenchymal stromal cells protect cancer cells from ROS-induced apoptosis and enhance the Warburg effect by secreting STC1. Mol Ther 2011 0.99
18 Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors. Eur J Immunol 2006 0.99
19 Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. Oncologist 2012 0.98
20 Multifunctional interleukin-1beta promotes metastasis of human lung cancer cells in SCID mice via enhanced expression of adhesion-, invasion- and angiogenesis-related molecules. Cancer Sci 2003 0.98
21 Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene. Tohoku J Exp Med 2008 0.95
22 Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells. Clin Cancer Res 2005 0.93
23 Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib. Oncology 2011 0.92
24 Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. J Clin Oncol 2006 0.90
25 Involvement of fractalkine/CX3CL1 expression by dendritic cells in the enhancement of host immunity against Legionella pneumophila. Infect Immun 2005 0.90
26 Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: an open-label trial. Jpn J Clin Oncol 2008 0.88
27 Randomized phase II trial of uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer: NJLCG 0601. Lung Cancer 2013 0.87
28 Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells. Eur J Immunol 2005 0.86
29 Intratracheal delivery of CX3CL1-expressing mesenchymal stem cells to multiple lung tumors. Mol Med 2009 0.85
30 Targeting angiogenesis and HGF function using an adenoviral vector expressing the HGF antagonist NK4 for cancer therapy. Mol Ther 2002 0.84
31 [A case of gastric adenosquamous carcinoma successfully treated with second-line chemotherapy (CPT-11 and CDDP)]. Gan To Kagaku Ryoho 2010 0.81
32 Identification of a CTL-directed epitope encoded by an intron of the putative tumor suppressor gene Testin of the common fragile site 7G region: a peptide vaccine candidate for HLA-B52+ and HLA-62+ cancer patients. Eur J Immunol 2003 0.80
33 A phase II study of weekly paclitaxel combined with carboplatin for elderly patients with advanced non-small cell lung cancer. Lung Cancer 2006 0.79
34 A change in the number of CCSP(pos)/SPC(pos) cells in mouse lung during development, growth, and repair. Respir Investig 2013 0.79
35 N-terminal deletion augments the cell-death-inducing activity of BAX in adenoviral gene delivery to nonsmall cell lung cancers. Oncogene 2003 0.78
36 A phase I study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer. J Thorac Oncol 2006 0.76
37 Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer. J Thorac Oncol 2006 0.76
38 Sequential irinotecan hydrochloride/S-1 for S-1-resistant inoperable gastric cancer: A feasibility study. Oncol Lett 2011 0.75
39 Suppression of surfactant protein A by an epidermal growth factor receptor tyrosine kinase inhibitor exacerbates lung inflammation. Cancer Sci 2008 0.75
40 Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancer. Cancer Res 2004 0.75
41 [Management of adverse effects of standard regimens for small cell lung cancer]. Nihon Rinsho 2015 0.75
42 [Change in patient satisfaction in outpatient chemotherapy unit--comparison in 2005 and 2008]. Gan To Kagaku Ryoho 2009 0.75
43 [Survey on the compliance of patients with continuous infusion of 5-fluorouracil via portable infusion pumps]. Gan To Kagaku Ryoho 2010 0.75
44 Adenocarcinoma with epidermal growth factor receptor gene mutations in three siblings. J Thorac Oncol 2008 0.75
45 [A case of gastric cancer treated with modified docetaxel, cisplatin and 5-fluorouracil(mDCF)with ingestion inability]. Gan To Kagaku Ryoho 2012 0.75
46 [A case of pulmonary Langerhans cell histiocytosis discovered by CT mass screening and followed by bronchoalveolar lavage]. Nihon Kokyuki Gakkai Zasshi 2006 0.75
47 [Standard chemotherapy of solid tumors. 1) Cancers of the respiratory system and breast]. Nihon Naika Gakkai Zasshi 2009 0.75